TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 431401

Group type: EXPERIMENTAL
Intervention: C+A (Carbenicillin + Amikacin)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: C+G (Carbenicillin + Gentamicin)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: C+S (Carbenicillin + Sisomicin)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: All groups (C+A, C+G, C+S)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Klebsiella spp. (pathogen)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Patients with persistent severe neutropenia
Number of subjects: 281
Study: 30514879

Group type: EXPERIMENTAL
Intervention: Continuous Energy Restriction (CER)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intermittent Energy Restriction (IER)
Number of subjects: 98
Study: 29749328

Group type: EXPERIMENTAL
Intervention: Oral vitamin E (400 mg/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral UDCA (15 mg/kg/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and UDCA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no drug except chemotherapy)
Number of subjects: 80
Study: 27156561

Group type: COMPARATOR
Intervention: Tofacitinib 1-15 mg BID, 20 mg QD
Number of subjects: 891

Group type: COMPARATOR
Intervention: Tofacitinib 1-15 mg BID
Number of subjects: 891

Group type: COMPARATOR
Intervention: Tofacitinib
Number of subjects: 891
Study: 25135737

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) in liver cirrhotic patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) in Child-Pugh C patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) in non-cirrhotic patients
Number of subjects: 46
Study: 22252804

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine monthly (DPm)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine every 2 months (DPalt)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 20446828

Group type: EXPERIMENTAL
Intervention: Unrestricted postoperative weight bearing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Partial weight bearing for 3 months
Number of subjects: 38
Study: 17161997

Group type: EXPERIMENTAL
Intervention: Use of recommended questionnaires for urinary incontinence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Use of recommended questionnaires for anal incontinence
Number of subjects: 150

Group type: COMPARATOR
Intervention: Use of recommended questionnaires for vaginal and pelvic floor problems
Number of subjects: 150
Study: 15653941

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg‐60 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11920997

Group type: EXPERIMENTAL
Intervention: Low WHR images selected by high WHR group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Low WHR images selected by low WHR group
Number of subjects: 2
Study: 9818845

Group type: EXPERIMENTAL
Intervention: Diastat (diazepam rectal gel)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 7656471

Group type: EXPERIMENTAL
Intervention: L-fucose in RA patients
Number of subjects: 135

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Early RA patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Advanced RA patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Female advanced RA patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Male advanced RA patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Female early RA patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Male early RA patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Correlation with disease activity
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Seropositive vs seronegative RA patients
Number of subjects: 135
Study: 2669002

Group type: EXPERIMENTAL
Intervention: Acetazolamide and thiamine (A + T)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 786422

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg daily for 5 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Soluble aspirin 3.6 g daily for 5 days
Number of subjects: 52
Study: 6773484

Group type: EXPERIMENTAL
Intervention: Parenteral amino acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertonic glucose plus amino acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hyperalimentation
Number of subjects: 0
Study: 31774526

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 2755

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio (WHR)
Number of subjects: 2755

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 2755
Study: 29255190

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) within 15 seconds
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 30 seconds
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 60 seconds
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 90 seconds
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 120 seconds
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 150 seconds
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 180 seconds
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) when umbilical cord pulsation ceased
Number of subjects: 720
Study: 26818528

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 120
Study: 24456339

Group type: EXPERIMENTAL
Intervention: Carbohydrate-enriched night meal (20-30% increase in carbohydrates during the second week)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Protein-enriched night meal (30-40% increase in protein during the third week)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No change in food composition (first week)
Number of subjects: 54
Study: 22215654

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (delivered intragastrically)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed liquid meal (delivered intragastrically)
Number of subjects: 0
Study: 21284343

Group type: EXPERIMENTAL
Intervention: High dose of arginine (20 g per day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Medium dose of arginine (12.3 g per day)
Number of subjects: 115
Study: 17714986

Group type: EXPERIMENTAL
Intervention: One painful clip applied to the earlobe
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: One painful clip applied to the nostril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Four painful clips applied simultaneously to the earlobe, nostril, eyebrow, and lower lip
Number of subjects: 19
Study: 16274036

Group type: EXPERIMENTAL
Intervention: Perioperative nutrition support (enteral and parenteral nutrition)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine postoperative parenteral nutrition
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Perioperative nutrition support (enteral and parenteral nutrition) in PD subgroup
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine postoperative parenteral nutrition in PD subgroup
Number of subjects: 82
Study: 11964588

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg-1 after induction of anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study: 9466469

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg orally, 12 and 2 hours before ischemia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg orally, 2 hours before ischemia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tourniquet arm (ischemia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no ischemia)
Number of subjects: 0
Study: 7623370

Group type: EXPERIMENTAL
Intervention: Hawksley random‐zero sphygmomanometer
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer
Number of subjects: 65
Study: 2649141

Group type: EXPERIMENTAL
Intervention: Mild induction and intensive consolidation therapy
Number of subjects: 358

Group type: COMPARATOR
Intervention: Mild post consolidation treatment
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis with intrathecal chemotherapy and intermediate dose i.v. methotrexate (MTX) and cytosine arabinoside (ARA-C)
Number of subjects: 358
Study: 333515

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (10 tablets given on an hourly regime)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31067324

Group type: EXPERIMENTAL
Intervention: QH treatments in specialist orthodontic clinics (QHS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: QH treatments in general dentistry (QHG)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: EP treatments in specialist orthodontic clinics (EPS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: EP treatments in general dentistry (EPG)
Number of subjects: 110
Study: 29036391

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Social Skills Training (CBSST)
Number of subjects: 149
Study: 27740929

Group type: EXPERIMENTAL
Intervention: 11.25- or 30-mg 3-month leuprolide acetate (LA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Basal LH levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3-month leuprolide acetate treatments
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Basal LH < 0.60 IU/L
Number of subjects: 42
Study: 25156340

Group type: EXPERIMENTAL
Intervention: Cardiovascular screening and exercise tolerance test prior to rehabilitation
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Negative cardiac screen and absence of exercise tolerance test failure
Number of subjects: 408
Study: 22257506

Group type: EXPERIMENTAL
Intervention: Home-based treadmill training (20-40 minutes, four times a week for six weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Home-based treadmill training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 20
Study: 19327317

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restrictive strategy (group 1)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Intensive insulin therapy (group 2)
Number of subjects: 337
Study: 17973956

Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g q.i.d.)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Number of subjects: 70
Study: 16163870

Group type: EXPERIMENTAL
Intervention: D/Sense 2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Seal & Protect 2.0
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 60
Study: 12965978

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole infusion plus endoscopic therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Intravenous omeprazole infusion alone
Number of subjects: 156
Study: 10725614

Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8729159

Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium imaging
Number of subjects: 93
Study: 1551058

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both surgical groups
Number of subjects: 109
Study: 3887560

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g once daily for 3 days
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g once daily for 7 days
Number of subjects: 310

Group type: COMPARATOR
Intervention: Amoxycillin 375 mg t.i.d. for 7 days
Number of subjects: 310
Study: 28668204

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2, day 1) and Pemetrexed (500 mg/m2, day 1)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2, day 1) and Vinorelbine (25 mg/m2, days 1 and 8)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Cisplatin with Pemetrexed
Number of subjects: 804

Group type: COMPARATOR
Intervention: Cisplatin with Vinorelbine
Number of subjects: 804
Study: 27632271

Group type: EXPERIMENTAL
Intervention: Ceramic inlays
Number of subjects: 28

Group type: COMPARATOR
Intervention: Composite fillings (control group)
Number of subjects: 28
Study: 24447003

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T-CBT)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioral therapy (FtF-CBT)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Both T-CBT and FtF-CBT
Number of subjects: 325
Study: 22905961

Group type: EXPERIMENTAL
Intervention: 5 Cs of Consultation (Contact, Communicate, Core Question, Collaboration, and Closing the Loop) educational session
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unstructured group
Number of subjects: 43
Study: 20418350

Group type: EXPERIMENTAL
Intervention: Exercise course
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Computer course
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study: 18616811

Group type: EXPERIMENTAL
Intervention: Single-dose pegfilgrastim 6 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Daily filgrastim 5 mug/kg
Number of subjects: 84
Study: 15960931

Group type: EXPERIMENTAL
Intervention: Samarium-153 (Quadramet) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 12610039

Group type: EXPERIMENTAL
Intervention: Acute administration of GLP-1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3-h preinfusion of GLP-1
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (without GLP-1)
Number of subjects: 18
Study: 10543556

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open saphenous vein harvest (OVH)
Number of subjects: 100
Study: 8740511

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Enalapril with calmodulin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Captopril with calmodulin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2
Study: 2066762

Group type: EXPERIMENTAL
Intervention: Carboplatin 200 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (CAC)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cisplatin 50 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (PAC)
Number of subjects: 164
Study: 6643398

Group type: EXPERIMENTAL
Intervention: Long-acting neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (withdrawal of long-acting neuroleptics)
Number of subjects: 41
Study: 31922425

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Subsequent therapies
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Second-line therapies
Number of subjects: 47
Study: 31021390

Group type: EXPERIMENTAL
Intervention: Single-fraction SBRT (12 Gy for ≥4-cm lesions or 16 Gy for <4-cm lesions)
Number of subjects: 160

Group type: COMPARATOR
Intervention: MFRT (30 Gy in 10 fractions)
Number of subjects: 160
Study: 27858223

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels assessed using the Physical Activity Questionnaire PAQ-A
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Physical Condition (PC) assessed using ALPHA-Fitness
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Perceived Barriers (PB) assessed using Self-Reported Barriers to Participation in Physical Activity questionnaire
Number of subjects: 143
Study: 26840067

Group type: EXPERIMENTAL
Intervention: Food Insulin Demand (FID) counting
Number of subjects: 26

Group type: COMPARATOR
Intervention: Carbohydrate Counting (CC)
Number of subjects: 26
Study: 23715264

Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral stress management (CBSM) with guided imagery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Individual information condition with muscle relaxation
Number of subjects: 150
Study: 22406012

Group type: EXPERIMENTAL
Intervention: Church-based nutrition program for African Americans including pastoral involvement, educational activities, church environmental changes, and peer counseling.
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1033
Study: 20664618

Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX) 5g/day for 1 week, then 10g/day for 2 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (skim milk powder) 5g/day for 1 week, then 10g/day for 2 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (skim milk powder)
Number of subjects: 54

Group type: COMPARATOR
Intervention: PolyGlycopleX (PGX) and Control (skim milk powder)
Number of subjects: 54
Study: 17625431

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (40 kDa) for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: lamivudine for 4 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (40 kDa) with adefovir for lamivudine-resistant patients
Number of subjects: 0
Study: 15798683

Group type: COMPARATOR
Intervention: 0 FRL (no ferrule, cast dowel/core and crown)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5/2 FRL (nonuniform ferrule, cast dowel/core and crown)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 FRL (2 mm ferrule, cast dowel/core and crown)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CRN (no root canal treatment, restored with a crown)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RCT/CRN (RCT treated tooth with a crown alone)
Number of subjects: 50
Study: 12020184

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 9498640

Group type: EXPERIMENTAL
Intervention: [N(ε)‐palmitoyl Lys (B29)] human insulin
Number of subjects: 9

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 9
Study: 7624200

Group type: EXPERIMENTAL
Intervention: Eccentric induction segment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction segment at eccentric position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short segment position within one half-field
Number of subjects: 0
Study: 1536410

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol with suxamethonium
Number of subjects: 40
Study: 6375800

Group type: EXPERIMENTAL
Intervention: Segmental phenolization
Number of subjects: 103

Group type: COMPARATOR
Intervention: Wedge excision
Number of subjects: 103
Study: 31828753

Group type: EXPERIMENTAL
Intervention: Restrictive intravenous (IV) fluid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-care intravenous (IV) fluid therapy
Number of subjects: 0
Study: 29254987

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (DPP‐4is)
Number of subjects: 67
Study: 27373605

Group type: EXPERIMENTAL
Intervention: Onoact® 50 Lyophilized powder (50mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rapibloc® concentrate IV (20mg/2mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12

Group type: COMPARATOR
Intervention: Concentrate formulation
Number of subjects: 12
Study: 25287144

Group type: EXPERIMENTAL
Intervention: Serelaxin (30 µg/kg per day)
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Both groups (Serelaxin and Placebo)
Number of subjects: 1161
Study: 21659904

Group type: EXPERIMENTAL
Intervention: Nonalcoholic beer (NAB) 1-1.5 L · d(‐1) for 3 weeks before and 2 weeks after the marathon
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo (PL) beverage
Number of subjects: 277
Study: 20427111

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 17

Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 17
Study: 18019463

Group type: EXPERIMENTAL
Intervention: Algorithm for medial soft tissue release based on kinematic data
Number of subjects: 81

Group type: COMPARATOR
Intervention: Surgeon's experience in making medial releases
Number of subjects: 81
Study: 16075782

Group type: EXPERIMENTAL
Intervention: Consecutive protocol (15 successive exposure nights)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intermittent protocol (3x 5 successive exposure nights, interspersed with 2 normoxic nights)
Number of subjects: 14
Study: 12118866

Group type: EXPERIMENTAL
Intervention: Dynamic contrast sensitivity measurements for letter stimuli of 2 sizes and 2 durations.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Simulated cataracts on dynamic contrast sensitivity.
Number of subjects: 68
Study: 9210061

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (tretinoin) at 120 or 150 mg/m2/day for 3 weeks followed by 1 week of rest, given as a single agent.
Number of subjects: 36
Study: 8357360

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference diet
Number of subjects: 18
Study: 3620293

Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 29455212

Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis (CGN) group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (low-risk pregnancies without CKD)
Number of subjects: 64